Date: 2011-07-12
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Transgene (France) Vivalis (France)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: licensing
collaboration
Action mechanism:
Disease:
Details: Vivalis and Transgene have entered into a commercial license and collaboration agreement to develop a process using the Vivalis EB66® cell line suitable for the manufacturing of Transgene MVA-based therapeutic vaccines.MVA-based therapeutic vaccines are one of the key technology pillars of Transgene. The company has three vaccine candidates in late stage clinical trials in cancer and infectious disease. These therapeutic vaccines are currently manufactured by Transgene in Chicken Embryo Fibroblasts (“CEF”). Transgene is considering significant investments to expand its manufacturing infrastructure over the coming years. Evaluating alternative manufacturing technology options for its products is part of Transgene’sindustrial strategy.
Financial terms: Vivalis will receive upfront and development milestone payments as well as royalty payments associated with product sales. Vivalis will also receive revenue from GMP manufacturing of initial clinical materials.
Latest news:
